Arginase-1 replacement therapy - Capricor Therapeutics
Latest Information Update: 25 May 2024
At a glance
- Originator Capricor Therapeutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Arginase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Hyperargininaemia
Most Recent Events
- 16 May 2024 Arginase-1 replacement therapy is available for licensing as of 16 May 2024 (Capricor Therapeutics Website, May 2024)
- 09 May 2024 Preclinical trials in Hyperargininaemia in USA (Parenteral)
- 09 May 2024 Pharmacodynamics data from a preclinical studies in Hyperargininemia released by Capricor Therapeutics